首页> Molecular cancer therapeutics> Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Valentina,Cutano

第一单位： AstraZeneca (United Kingdom) Cambridge United Kingdom.

作者： Valentina,Cutano ^[1] ; Shanade,Dunn ^[1] ; Sungmi,Park-Chouinard ^[2] ; Eleanor M,Wigmore ^[1] ; Qing,Wu ^[2] ; Lambert,Montava Garriga ^[2] ; Lorna,Hopcroft ^[1] ; David,Esopi ^[2] ; Michele,Chirichella ^[1] ; Siyu,Liu ^[2] ; Cath,Eberlein ^[3] ; Ming,Tang ^[2] ; Hyung Joo,Lee ^[4] ; Wenhao,Zhang ^[5] ; Megan,Callahan ^[5] ; Barrett R B,Nuttall ^[4] ; Daniel,Barrell ^[1] ; Toby,Gurran ^[1] ; Jennifer,Hillis ^[6] ; Adam,Spruce ^[2] ; Ramy,Elgendy ^[7] ; Jenna,Bradley ^[1] ; Chang,Kim ^[2] ; Sara,Talbot ^[1] ; Lingling,Dai ^[8] ; Laura H,Rosenberg ^[2] ; Susana,Ros ^[1] ; Huayang,Liu ^[9] ; Neeraj,Aryal ^[2] ; Jerome T,Mettetal ^[4] ; Ho Man,Chan ^[9] ; Ultan,McDermott ^[1] ; Functional,Genomics Centre ^[1] ; Simon T,Barry

作者单位： AstraZeneca (United Kingdom) Cambridge United Kingdom. ^[1] AstraZeneca (United Kingdom) United States. ^[2] AstraZeneca Cheshire United Kingdom. ^[3] AstraZeneca (United States) Waltham, MA United States. ^[4] AstraZeneca (United Kingdom) Waltham, MA United States. ^[5] Cancer Research Horizons Cambridge, Cambridgeshire United Kingdom. ^[6] AstraZeneca (Sweden) Mölndal Sweden. ^[7] AstraZeneca (United States) Boston United States. ^[8] AstraZeneca (United States) United States. ^[9]

DOI 10.1158/1535-7163.MCT-25-1006

PMID 41983950

发布时间 2026-04-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交